Use of Gain-of-Function Screening to Identify miRNAs Involved in Paclitaxel Resistance in Triple-Negative Breast Cancer
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252413630 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Stéphane Nemours und 11 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Oncology Group, Biogipuzkoa Health Research Institute, 20014 San Sebastian, Spain. Hauptthemen laut MEDLINE: MicroRNAs, Triple Negative Breast Neoplasms, Paclitaxel, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III (ISCIII), Spain, European Union, Departamento de Industria del Gobierno Vasco, Spain.
Abstract (Originalsprache)
Paclitaxel is a widely used chemotherapeutic agent for the treatment of breast cancer (BC), including as a front-line treatment for triple-negative breast cancer (TNBC) patients. However, resistance to paclitaxel remains one of the major causes of death associated with treatment failure. Multiple studies have demonstrated that miRNAs play a role in paclitaxel resistance and are associated with both disease progression and metastasis. In the present study, we used a miRNA-encoding lentiviral library as a gain-of-function screen for paclitaxel resistance in the MDA-MB-231 TNBC cell line. We identified that miR-181b, miR-29a, miR-30c, miR-196 and miR-1295 conferred a resistant phenotype to cells. The expression of miR-29a also induced resistance to eribulin and vinorelbine, while miR-181b and miR-30c induced resistance to vinorelbine. We measured the levels of these miRNAs in breast cancer patients and observed higher levels of miR-29a in treatment-refractory patients. Taken together, we suggest that miR-29a and miR-181b may be good candidates for miRNA inhibition to overcome resistance to chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Oncology Group, Biogipuzkoa Health Research Institute, 20014 San Sebastian, Spain.
- Department of Personalized Medicine, NASERTIC, Government of Navarra, 31011 Pamplona, Spain.
- Breast Cancer Group, Biogipuzkoa Health Research Institute, 20014 San Sebastian, Spain.
- Gipuzkoa Cancer Unit, OSI Donostialdea-Onkologikoa Foundation, Paseo Dr Begiristain 121, 20014 San Sebastian, Spain.
- Department of Pathology, Hospital Universitario Donostia Osakidetza, 20014 Donostia, Spain.
- InteRNA Technologies, 3584 Utrecht, The Netherlands.
ORCID-Profile: Stéphane Nemours, Carla Solé, María Armesto, María Arestin, Ander Urruticoechea, Charles H Lawrie
Förderung
- Instituto de Salud Carlos III (ISCIII), Spain
- European Union
- Departamento de Industria del Gobierno Vasco, Spain
Zitieren
APA
Nemours, S., Solé, C., Goicoechea, I., Armesto, M., Arestin, M., Urruticoechea, A., Rezola, M., López, I. Á., Schaapveld, R., Schultz, I., Zhang, L., & Lawrie, C. H. (2024). Use of Gain-of-Function Screening to Identify miRNAs Involved in Paclitaxel Resistance in Triple-Negative Breast Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252413630
Vancouver
Nemours S, Solé C, Goicoechea I, Armesto M, Arestin M, Urruticoechea A, et al. Use of Gain-of-Function Screening to Identify miRNAs Involved in Paclitaxel Resistance in Triple-Negative Breast Cancer. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252413630
BibTeX
@article{Nemours2024,
author = {Nemours, Stéphane and Solé, Carla and Goicoechea, Ibai and Armesto, María and Arestin, María and Urruticoechea, Ander and Rezola, Marta and López, Isabel Álvarez and Schaapveld, Roel and Schultz, Iman and Zhang, Lei and Lawrie, Charles H},
title = {Use of Gain-of-Function Screening to Identify miRNAs Involved in Paclitaxel Resistance in Triple-Negative Breast Cancer},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252413630}
}
EUVIMED